Despite encouraging clinical data, copyright's Vyndamax, a treatment for hereditary transthyretin-mediated amyloidosis (hATTR), is encountering substantial resistance from pharmacy benefit managers. The companies are often building obstacles to reimbursement, like high cost requirements and PA th